Suormala T, Ramaekers V T, Schweitzer S, Fowler B, Laub M C, Schwermer C, Bachmann J, Baumgartner E R
Metabolic Unit, University Children's Hospital, Basel, Switzerland.
J Inherit Metab Dis. 1995;18(6):689-700. doi: 10.1007/BF02436758.
We describe a simple method for the detection of biotinidase Km-variants and detailed biochemical investigations in 5 such patient. They were detected among 103 patients with plasma biotinidase activity which ranged from undetectable to 30% of the mean normal value. Two different types of biotinidase Km-variants were found. (1) In 3 infants biotinidase had a single 105-430-fold elevated Km for biocytin. Biotinidase showed very low activities (0.2-4% of the mean normal value) in the routine colorimetric assay and was not functional in vivo. Accordingly, these patients presented with classical clinical illness. (2) In two patients biotinidase showed biphasic kinetics indicating the presence of one component with a normal Km and reduced Vmax (1.7% and 12%), and another with 330- and 59-fold elevated Km, respectively. In these two patients, biotinidase proved to be at least partially functional in vivo. However, the first patient developed severe symptoms and biotin deficiency late, at the age of 10-15 years, and the second had marginal biotin deficiency at the age of 2 years but no clinical symptoms. Comparative studies revealed that both patients had more severe biotin deficiency than age-matched patients with similar levels of residual biotinidase activity and a single normal Km. Therefore, all patients with residual biotinidase activity should be evaluated for the presence of a Km-mutation, since such patients should be treated with biotin. These can easily be detected by including a second substrate concentration (1.5 mmol/L) in the routine colorimetric biotinidase assay which is performed with 0.15 mmol/L biotin. Increased activity with the higher substrate concentration indicates the presence of a Km-mutation. Detailed kinetic studies are needed to evaluate the distinct forms of Km-variants.
我们描述了一种检测生物素酶Km变异体的简单方法,并对5例此类患者进行了详细的生化研究。这些患者是在103例血浆生物素酶活性范围从检测不到到正常平均值30%的患者中发现的。发现了两种不同类型的生物素酶Km变异体。(1)在3例婴儿中,生物素酶对生物胞素的Km升高了105 - 430倍。在常规比色测定中,生物素酶活性非常低(为正常平均值的0.2 - 4%),且在体内无功能。因此,这些患者表现出典型的临床疾病。(2)在2例患者中,生物素酶表现出双相动力学,表明存在一种Km正常但Vmax降低(分别为1.7%和12%)的成分,以及另一种Km分别升高330倍和59倍的成分。在这2例患者中,生物素酶在体内至少部分有功能。然而,第一例患者在10 - 15岁时出现严重症状和生物素缺乏较晚,第二例患者在2岁时存在边缘性生物素缺乏但无临床症状。比较研究表明,这两名患者的生物素缺乏比年龄匹配、残余生物素酶活性水平相似且Km单一正常的患者更严重。因此,所有残余生物素酶活性的患者都应评估是否存在Km突变,因为这类患者应接受生物素治疗。通过在常规比色生物素酶测定(使用0.15 mmol/L生物素进行)中加入第二种底物浓度(1.5 mmol/L),可以很容易地检测到这些突变。底物浓度较高时活性增加表明存在Km突变。需要进行详细的动力学研究来评估Km变异体的不同形式。